Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VB-01
- Development stage
- Phase 1
- Lead developer
- Viscofan
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Epicardial
01
Overview
VB-01 is an advanced therapy medicinal product (ATMP) consisting of allogeneic adipose-derived mesenchymal stem cells (aASCs) seeded onto a proprietary, biocompatible collagen membrane scaffold. Developed by Viscofan BioEngineering (a division of Viscofan), this regenerative therapy is intended for the treatment of ischaemic cardiomyopathy and chronic heart failure. The product is applied surgically to the epicardium, typically during coronary artery bypass grafting (CABG). The collagen membrane serves as a delivery vehicle that enhances the localized retention and survival of the stem cells at the site of myocardial injury. Once applied, the aASCs exert their therapeutic effects primarily through paracrine signaling, secreting a variety of pro-angiogenic, anti-inflammatory, and anti-fibrotic factors. These factors aim to stimulate myocardial repair, improve cardiac remodeling, and enhance overall heart function in patients with damaged heart tissue.
- Other names
- allogeneic adipose-derived stem cells on collagen membraneaASCs on collagen membraneallogeneic adipose-derived mesenchymal stem cells on collagen membrane
Beyond the preview
Go deeper on VB-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VB-01.